Citizens JMP raised the firm’s price target on Enanta (ENTA) to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals expects cash and continuing Mavyret income to fund operations into fiscal 2028, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: